STOCKS TELEGRAPH

Tag: ENTX

  • Entera Bio, Ltd. (ENTX) Stock Skyrockets After Being Granted European Patent

    Entera Bio, Ltd. (ENTX) Stock Skyrockets After Being Granted European Patent

    Entera Bio, Ltd. (ENTX) stock prices surged by a massive 24.76% as of the market closing on June 17th, 2021, bringing the price per share up to USD$5.19 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock inch up by another 0.19%, bringing it up to USD$5.20.

    Patent Granted

    The company announced on June 17th, 2021 that it had been granted a patent titled “Methods and Compositions for Oral Administration of Protein’s” by the European Patent office. The patent secures a marketspace for the companies PTH formulations that are currently in advanced clinical stages for osteoporosis and hypoparathyroidism.

    Safeguarding Intellectual Property

    The critical patent covers leading PTH treatment products that are based on the company’s platform technology. The newly granted patent, in conjunction, with a myriad of other patents that cover oral formulations and target indications, facilitate the provision of robust protection for ENTX’s intellectual property. Besides the EU patent, the company has been granted strategic patents from countries including, but not limited to, USA, China, Japan, Australia, and New Zealand.

    Scope of Patent

    Especially promising was the recent news of the successful completion of the none-month time window during which the patent could have been challenged. The company is keen to consolidate its position as a market leader in the oral delivery of proteins in the wake of the upcoming six-month BMD result reports from the Phase 2 study. Phase 2 is scheduled for the second quarter of fiscal 2021. The company also has plans to potentially initiate a pivotal Phase 3 study next year, designed to evaluate the company’s oral PTH treatment of osteoporosis.

    About ENTX

    ENTX is an established leader in the development of large molecule therapeutics that are delivered orally, with the company targeting areas with significant unaddressed medical needs. Penetration is highest in markets where the use of injectable therapies is limited for various reasons, including cost, convenience, or compliance issues for patients. The company is spearheading efforts to address standard technical challenges of poor absorption high variability, and the inability to effectively ensure delivery of large molecules to the intended locations in the body.

    Future Outlook for ENTX

    Armed with this ground-breaking development, ENTX is poised to continue its trajectory of success by preparing itself to successfully execute the market proliferation of its patented treatment. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Entera Bio Ltd (ENTX) stock plunged in the pre-market trading session; Here’s what’s happening

    Entera Bio Ltd (ENTX) stock showed a positive movement by 8.7% in the recent trading session where the stock’s price was $4.00. It previously closed at $3.68. However, in the pre-market trading session, the stock plunged by 9% at the time of writing.

    Recent news related to Entera Bio comes in the form of another Bio-pharmaceutical company-Abeona Therapeutics recently announcing two new independent board members to its board of directors. One of the newly appointed members includes a member of the Board of Directors in Entera Bio (ENTX).

    Entera Ltd. (ENTX)’s core focus

    Entera Bio Ltd. is a biotech company that specifically focuses on delivering large molecule therapeutics through oral administration. This large molecule therapeutics is used in the base of clinically-unmet medical needs. Administration of injectable therapies is expensive as compared to oral therapies which is why the focus on the latter is more efficient and easily supplied. However, oral administration may come upon hurdles of high-exposure to open air contamination, poor absorption and lack of synthetic absorber for large molecule dosage. ENTX has set its sight to deal with these technicalities to bridge the gap.

    BOD member of ENTX has joined the Board committee of Abeona Therapeutics Ltd.

    The member of the Board of Directors in Entera (ENTX) who is now serving in the newly appointed chair of BOD in Abeona, is known by the name of Faith L. Charles. Ms. Charles has 30 years of experience in legal profession and has specifically served sciences based companies. She has worked with several such companies. In Entera her title is that of the member Audit Committee and Chair of the Compensation Committee. Furthermore her business conduct is always associated with that of a valuable insight provider of capital markets and expert in corporate governance.

    How is the overall outlook for ENTX stock?

    On 18th March, ENTX released the financial and operating results for the fourth quarter and Full Year ended 31 December, 2020.

    The highlights for its operational activities for the Full-Year 2020 are as such:

    • Entera (ENTX) had the approval of EB613 IND from the FDA, for the Treatment of Osteoporosis. This allows progress for initial U.S clinical trials.
    • Successfully achieved primary endpoint for phase 2 clinical trial of EB613
    • Data regarding and including Bone Mineral Density is expected in Q2:21
    • Amgen Collaboration is showing progress by further evaluation of molecules like GLP-2

    The financial results for its FY 2020 showed overall improvement with the only relative underperformances:

    • Revenues for 31, Dec FY 2020 were $365,000 compared to $236,000 for 31, Dec FY 2019
    • Operating expenses were $11.3 million for 31, Dec FY 2020 as compared to $11.5 million for 31, Dec FY 2019
    • R&D expenses were $6.4 million for FY 2020 compared to $7.2 million for FY 2019
    • General administrative expenses were $4.9 million for 31, Dec FY 2020 compared to $4.3 million in 31, Dec FY 2019
    • Cash and cash equivalents were equal to $8.6 million at the end of FY 2020 compared to $15.2 million in 31, Dec FY 2019

    Entera (ENTX) consists of a lot of clinical trials in the pipelines that are showing progress. The continued advances in these trials will give the operational outcomes a boost for ENTX stock in the year 2021. These operational outcomes can then be further reflected on its financial activity health.

  • Market Movers: What changed for these 37 stocks while you were sleeping

    Market Movers: What changed for these 37 stocks while you were sleeping

    Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will begin a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. Company’s 52-week ranged between $0.53 to $3.10. Analysts have a consensus price target of $7.75.
    SELLAS Life Sciences Group Inc. (SLS) stock plunged -24.18% to $13.39 in the pre-market trading. The most recent rating by Oppenheimer, on November 01, 2018, is an Outperform.
    Veru Inc. (VERU) tumbled over -11.89% at $5.26 in pre-market trading today. The firm recently declared that it has exclusively licensed phase 3 clinical stage targeted therapy for endocrine resistant metastatic breast cancer.
    Before the trading started on December 11, 2020, Professional Diversity Network Inc. (IPDN) is down -25.0% to reach $1.53. It has been trading in a 52-week range of $0.76 to $3.98.
    Neos Therapeutics Inc. (NEOS), a Drug Manufacturers – Specialty & Generic company, dropped about -16.36% at $0.6832 in pre-market trading Friday after announcing definitive merger agreement with Aytu BioScience, pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Callon Petroleum Company (CPE) is down more than -0.53% at $15.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 7.71% to $15.08 in the last trading session.
    C3.ai Inc. (AI) stock moved down -5.38 percent to $123.0 in the pre-market trading. The company lately declared the pricing of its initial public offering of 15,500,000 shares of its Class A common stock at a price of $42.00 per share.
    Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) shares are trading up 2.21% at $1.85 at the time of writing. Company’s 52-week ranged between $1.00 to $6.90. Analysts have a consensus price target of $14.
    Regulus Therapeutics Inc. (RGLS) stock plunged -9.92% to $1.09 in the pre-market trading. The healthcare company revealed closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is a Neutral.
    Range Resources Corporation (RRC) stock plunged -4.79% to $7.35 in the pre-market trading. The most recent rating by Stephens, on November 16, 2020, is an Overweight.
    Zedge Inc. (AMEX: ZDGE) shares are trading up 23.7% at $6.68 at the time of writing after reporting first fiscal quarter revenue growth of 85% and record overall quarterly financial results. Company’s 52-week ranged between $0.66 to $4.70. Analysts have a consensus price target of $3.
    Hennessy Capital Acquisition Corp. IV (HCAC), a Shell Companies company, dropped about -5.82% at $20.72 in pre-market trading Friday.
    Editas Medicine Inc. (EDIT) grew over 0.84% at $67.4 in pre-market trading today. The company recently publicized submission of IND application for EDIT-301 with the FDA.
    Greenwich LifeSciences Inc. (GLSI) is down more than -9.3% at $65.5 in pre-market hours Friday December 11, 2020 following the today’s announcement of poster presentation on its GP2 phase III clinical trial design for recurring breast cancer. The stock had jumped over 26.48% to $72.22 in the last trading session.
    Silver Spike Acquisition Corp. (SSPK) is down more than -2.78% at $14.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 37.27% to $14.40 in the last trading session.
    Biocept Inc. (BIOC) stock plunged -3.07% to $5.68 in the pre-market trading after declaring results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The most recent rating by Chardan Capital Markets, on November 14, 2017, is a Buy.
    W&T Offshore Inc. (NYSE: WTI) shares are trading down -6.02% at $2.5 at the time of writing following the firm provided an operational update regarding fourth quarter 2020 production. Company’s 52-week ranged between $1.07 to $6.10.
    Before the trading started on December 11, 2020, Platinum Group Metals Ltd. (PLG) is up 1.93% to reach $5.27. It has been trading in a 52-week range of $0.86 to $5.20.
    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -24.72% at $6.12 in pre-market trading Friday after the company and Neos Therapeutics declared definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Torchlight Energy Resources Inc. (TRCH) stock soared 13.78% to $0.7226 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.
    Before the trading started on December 11, 2020, Energy Fuels Inc. (UUUU) is up 1.64% to reach $3.1 following the announcement from the company that that its President and CEO Mark S. Chalmers will be presenting live at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 11:40 AM (EST). It has been trading in a 52-week range of $0.78 to $2.99.
    Ashford Hospitality Trust Inc. (NYSE: AHT) shares are trading up 8.04% at $4.3 at the time of writing. Company’s 52-week ranged between $1.27 to $29.44.
    ClearOne Inc. (CLRO) stock plunged -7.2% to $2.45 in the pre-market trading after declaring that it has appointed Chromasound PLC, based in Budapest, Hungary, as its newest distribution partner. The most recent rating by Singular Research, on August 16, 2018, is a Buy – long-term.
    ReWalk Robotics Ltd. (NASDAQ: RWLK) shares are trading up 3.7% at $1.4 at the time of writing after revealing a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury (SCIs) to apply for the procurement of a ReWalk 6.0 exoskeleton system. Company’s 52-week ranged between $0.41 to $2.71. Analysts have a consensus price target of $1.50.
    Progenity Inc. (PROG) grew over 9.32% at $4.34 in pre-market trading today. The firm recently reported closing of the convertible senior notes offering and partial exercise of the Initial purchaser’s option to purchase additional notes.
    Boxlight Corporation (BOXL) is down more than -7.69% at $1.8 in pre-market hours Friday December 11, 2020. The stock had jumped over 17.47% to $1.95 in the last trading session.
    Lemonade Inc. (LMND), a Insurance – Property & Casualty company, rose about 0.7% at $100.4 in pre-market trading Friday. The company recently declared that residents of France can now get renters insurance instantly, anytime, and from any device – as well as file claims and get paid in seconds through the Lemonade app.
    ObsEva SA (OBSV) lost over -2.54% at $2.3 in pre-market trading Friday December 11, 2020 after announcing topline 52-week PRIMROSE 1 and 76-week PRIMROSE 2 results of Yselty, in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids.
    Amplify Energy Corp. (AMPY) is down more than -27.33% at $1.09 in pre-market hours Friday December 11, 2020 following the commencement of an underwritten public offering of 8,548,485 shares of its common stock by certain of its stockholders which are affiliates of Fir Tree Capital Management L.P. The stock had jumped over 11.94% to $1.50 in the last trading session.
    Before the trading started on December 11, 2020, Hoth Therapeutics Inc. (HOTH) is up 0.54% to reach $1.85 after the firm revealed that it has received approval to commence phase 1b clinical trial of BioLexa for the treatment of Atopic Dermatitis in humans. It has been trading in a 52-week range of $1.60 to $7.25.
    RMG Acquisition Corp. (RMG) grew over 6.6% at $22.29 in pre-market trading today after declaring stockholder meeting Date of December 28, 2020.
    Marathon Patent Group Inc. (MARA) is down more than -10.34% at $4.68 in pre-market hours Friday December 11, 2020. The company recently stated that it has entered into a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners. The stock had jumped over 9.21% to $5.22 in the last trading session.
    Before the trading started on December 11, 2020, Inseego Corp. (INSG) is up 7.26% to reach $13.15. The firm today reported that the it is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. It has been trading in a 52-week range of $3.91 to $15.25.
    Entera Bio Ltd. (ENTX) tumbled over -7.56% at $1.1 in pre-market trading today after revealing FDA approval of IND application for EB613 – an oral human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.
    OncoCyte Corporation (OCX) stock moved up 3.23 percent to $2.24 in the pre-market trading. The firm recently reported that it will host a key opinion leader (KOL) call on the Company’s proprietary DetermaRx™ and DetermaIO™ molecular tests for cancer treatment selection on Tuesday, December 15, 2020 at 11:00am Eastern Time.
    ZK International Group Co. Ltd. (ZKIN) lost over -4.98% at $2.1 in pre-market trading Friday December 11, 2020 after declaring that it signed a letter of intent with Tuopeng Industrial, a prominent construction and real estate company.
    Before the trading started on December 11, 2020, Arbutus Biopharma Corporation (ABUS) is up 15.8% to reach $4.25. It has been trading in a 52-week range of $0.88 to $9.02 following the declaration of additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

  • Don’t Miss these 15 Biotechnology Value Stocks

    Biotech and Major Pharmaceuticals are back in the news with the Covid-19 Pandemic. Life science investors basically endorse developments that might decide the human race’s future, but what would invest in ‘cures’ mean from a cash flow point of view?
    On Thursday, a panel of independent health professionals voted 17-4 in support of the Food and Drug Administration(FDA), providing emergency permission to the applicant for the COVID-19 vaccine from BioNTech and Pfizer Inc.
    In other news Gilead Sciences Inc (GILD) revealed that it would buy MYR GmbH in cash for roughly EUR 1.15 billion ($1.39 billion), granting it access to the German biotech company’s therapy for extreme viral hepatitis.
    In yesterday’s trading session, the following stocks were the major key players.

    Immutep Limited (NASDAQ:IMMP) shares were trading up 163.43% at $5.69 at the time of writing on Thursday after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

    Immutep Limited (NASDAQ:IMMP) share price went from a low point around $0.53 to briefly over $3.10 in past 52 weeks, though shares have since pulled back to $5.69. IMMP market cap has remained high, hitting $280.46M at the time of writing.

    If we look at the recent analyst rating IMMP, B. Riley FBR initiated coverage on IMMP shares with a Buy rating.

    TG Therapeutics Inc. (TGTX) stock soar by 40.85% to $41.72 after reportingpositive topline results from the ULTIMATE I & II Phase 3 studies evaluating Ublituximab Monotherapy for the treatment of patients with multiple sclerosis. The most recent rating by JP Morgan, on September 01, 2020, is at an Overweight.

    Heat Biologics Inc. (HTBX) last closed at $0.93, in a 52-week range of $0.19 to $4.30.

    Sangamo Therapeutics Inc. (NASDAQ:SGMO) Shares headed rising, higher as much as 52.98%. Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO), on December 7, 2020 declared updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. The most recent rating by BofA Securities, on September 08, 2020, is at a Buy.

    Entera Bio Ltd. (NASDAQ:ENTX) rose 8.18% after gaining more than $0.09 on Thursday following the firm revealed FDA approval of IND application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.

    Aytu BioScience Inc. (AYTU) last closed at $8.13, in a 52-week range of $3.35 to $29.90 after announcing definitive merger agreement with Neos Therapeutics, creating a combined $100M revenuespecialty pharmaceutical company.

    Amarin Corporation plc (AMRN) stock soar by 8.04% to $4.97. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Editas Medicine Inc. (NASDAQ:EDIT) Shares headed rising, higher as much as 32.15% following an announcement from the company that it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301. The most recent rating by Wells Fargo, on December 10, 2020, is at an Overweight.

    Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) rose 9.04% after gaining more than $0.15 on Thursday.

    Akebia Therapeutics Inc. (AKBA) last closed at $2.95, in a 52-week range of $2.09 to $13.71. The firm recently revealed the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 5.37% to $7.65. The company recently announced transactions with Royalty Pharma (RPRX) and Athyrium Capital Management, LP, totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    Acasti Pharma Inc. (NASDAQ:ACST) Shares headed rising, higher as much as 1.70%. The company on November 16, 2020 released its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. The most recent rating by Oppenheimer, on September 01, 2020, is at a Perform.

    Ocugen Inc. (NASDAQ:OCGN) fall -1.79% after losing more than -$0.01 on Thursday after reporting that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020.

    Inovio Pharmaceuticals Inc. (INO) last closed at $11.36, in a 52-week range of $2.42 to $33.79. The firm recently revealedthe successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. Analysts have a consensus price target of $13.71.

    Cellectar Biosciences Inc. (CLRB) stock soar by 3.47% to $2.09. The most recent rating by Oppenheimer, on July 01, 2020, is at an Outperform.

  • Top Stocks to Watch Today as Retail Bankruptcies Dampen Outlook

    Top Stocks to Watch Today as Retail Bankruptcies Dampen Outlook

    It’s a mixed day ahead for the U.S equity markets, as the full effects of the coronavirus begin to take effect. The number of permanent job losses in the restaurant market is on the rise, pointing to more pain for the U.S labor market. The number of retail bankruptcies is on the rise too. The Wall Street Journal has reported that the number of bankruptcies is rising faster than many analysts had anticipated. However, even in this environment, there are stocks that are on the rise ahead of markets. The biggest gainers in the current market are mainly in the biotech and energy sectors and are driven by product developments and strong earnings by various industry players. Some of the big players ahead of markets are as below:

    Entera Bio Ltd [NASDAQ:ENTX]

    This is one of the top gainers in pre-market trading and is up by 81% at the time of writing. It’s strong upside momentum after the company announced that it had recorded positive results on its market survey for oral results.  The company has stated that about 85% of clinicians that took part in the survey said they would prescribe PTH in the treatment of moderate and even severe osteoporosis. This is a big deal because PTH can be used to handle the unmet needs that include the improvement of patient comfort. For Entera Bio Ltd, this means that there is a potential to grow in the multibillion-dollar global market focused on the treatment of Osteoporosis. The exposure on market potential by this survey has excited the market and given this stock a renewed optimism.

    Helix Energy Solutions Group Inc [NASDAQ:HLX]

    Helix  Energy Solutions is another top gainer pre-market and is up by 24.51%. The stock’s rally following the release of strong Q2 earnings that beat analysts’ expectations. The company reported an EPS of $0.04 beating analyst expectations of an EPS loss of $0.02.  The company’s revenues also rose to $199.15 million in the quarter, beating analyst expectations by 14.67%. This points to a strengthening of the company’s position in the market.

    Liquid Media Group Ltd [NASDAQ:YVR]

    Liquid Media Group Ltd is another top performer pre-market and is up by 80%. This comes after the company’s announcement that it had partnered with two digital agencies with the goal of transforming its streaming platform. It will be interesting to see how news of the partnership plays out in its price action when markets open.